Shareholders


Audited by PwC

Novozymes’ stock consists of two types: A and B shares, both with a nominal value of DKK 10 per share. All A common stock is held by Novo A/S, and an A share carries 10 times as many votes as a B share. 

A stock B stock Total
Common stock (DKK)

107,487,200

542,512,800

650,000,000

Number of shares

10,748,720

54,251,280

65,000,000

Number of votes

1,074,872,000

542,512,800

1,617,384,800

Voting rights (%)

66.5

33.5

100

Novo A/S holds 25.5% of the total outstanding common stock and, through its holding of the A common stock and a proportion of the B common stock (5,826,280 shares), controls 70.1% of the votes. Novo A/S is fully owned by the Novo Nordisk Foundation, which is why Novozymes is included in the consolidated financial statements of the Novo Nordisk Foundation. Novo A/S is domiciled in Gladsaxe, Denmark.

At the end of 2009 Novozymes had roughly 53,000 shareholders, of which around 98% are private investors, mainly in Denmark. Thirty institutional shareholders own approximately 54% of the B stock (this includes Novozymes A/S’ holding of treasury stock and Novo A/S’ holding). Investors outside Denmark hold approximately 53%.

Novozymes holds 5.2% of the B stock, equivalent to 4.3% of the total number of shares outstanding.

According to the Danish Companies Act, shareholders must notify the company if they hold at least 5% of the company’s common stock. No shareholders, except Novo A/S, hold more than 5% of Novozymes’ common stock.

My Report
SHAREHOLDER DISTRIBUTION OF B COMMON STOCK
FusionCharts.
Denmark (31%)
North America (14%)
UK (30%)
Novo A/S (11%)
Own shares (5%)
Rest of World (2%)
Rest of Europe (7%)